| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a36c66685971b78daf233b5999ead4c2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 |
| filingDate |
2017-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2d7d40b6aaaf5a52e364347ab2c888c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f4cacd65ef8c7dd2541bb16b565a918
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b98f6ce82de0c9cb2d2495df88f0d9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8452a7f4a4260cbf1445f0745594a718
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e7d728685b5bbab131895ce3f9462bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_459a5103e0f6d5ef28b01d02a4caa308
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26c88b6c0b0a03563ec5ab89503f857a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b1eae046e1f96694ce10971b3ad7d0b |
| publicationDate |
2017-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017129094-A1 |
| titleOfInvention |
Use of egfr/her2 receptor tyrosine kinase inhibitor in preparing drugs for treating cancers induced by her2 mutation |
| abstract |
The present invention relates to the use of an EGFR/HER2 receptor tyrosine kinase inhibitor in preparing drugs for treating cancers induced by HER2 mutation. In particular, the present invention relates to the use of a compound as shown in formula A or a pharmaceutically acceptable salt thereof in preparing drugs for treating cancers induced by HER2 mutation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113116879-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110314159-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109504769-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111110676-A |
| priorityDate |
2016-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |